January 19, 2023
Japan’s key reimbursement policy panel on January 18 approved the cost-effectiveness assessment (CEA) results for Eli Lilly’s Emgality (galcanezumab), Takeda Pharmaceutical’s Revestive (teduglutide), and Gilead Sciences’ Veklury (remdesivir), putting them all in line for downward price adjustments. Emgality, a migraine...read more